medigraphic.com
ISSN 2007-3178 (Impreso)
Asociación Mexicana de Cirugía Bucal y Maxilofacial, Colegio Mexicano de Cirugía Bucal y Maxilofacial, A.C.

2018, Número 2

<< Anterior Siguiente >>

Rev Mex Cir Bucal Maxilofac 2018; 14 (2)


Osteonecrosis de los maxilares inducida por bifosfonatos (OMB): revisión de la literatura y análisis de ocho casos

Cadena AJL, Romero AJC, Lara GNV, Tapia PDC

Idioma: Español
Referencias bibliográficas: 39
Paginas: 89-98
Archivo PDF: 306.30 Kb.


RESUMEN

Los bifosfonatos (BP) se han utilizado eficientemente para tratar la osteoporosis, la hipercalcemia, metástasis ósea de los tumores malignos sólidos y la enfermedad del hueso de Paget; sin embargo, se han reportado complicaciones como la osteonecrosis maxilar inducida por bifosfonatos (OMB). Objetivo: Realizar una revisión de casos de OMB en el Hospital General de Zona Núm. 57 del IMSS en un periodo comprendido de junio de 2010 a junio de 2015. Resultados: Se identificaron ocho pacientes con OMB. De los pacientes estudiados, tres (37.5%) eran hombres y cinco (62.5%) mujeres, con una edad media de 69 años. En cuanto a la enfermedad asociada, 75% (seis pacientes) presentaba patología oncológica: tres pacientes cáncer de mama y tres pacientes cáncer de próstata; 25% (dos pacientes) se asociaba a osteoporosis. Conclusiones: Los bifosfonatos son los medicamentos ideales para tratar metástasis óseas y osteoporosis. En el estadio I el tratamiento ideal es el uso prolongado de antibioticoterapia. El legrado superficial de las lesiones de OMB parece ser el tratamiento más eficaz para pacientes que se encuentren en un estadio II leve y el legrado profundo para los pacientes con grado II severo y grado III leve, combinado con una terapia antibiótica de larga duración y el uso de colutorios orales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008; 3 Suppl 3: S131-139.

  2. Russell G. Bisphosphonates: the first 40 years. Bone. 2011; 49 (1): 2-19.

  3. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068: 367-401.

  4. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014; 19 (2): 403-410.

  5. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9 (32): 2643-2658.

  6. Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des. 2010; 16 (27): 2961-2969.

  7. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011; 48 (4): 677-692.

  8. Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronato and risedronate for postmenopausal osteoporosis. Curr Med Res Opin. 2006; 22 (5): 919-928.

  9. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74 (11): 1385-1393.

  10. Ferlito S, Puzzo S, Palermo F, Verzi P. Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. Br J Oral Maxillofac Surg. 2012; 50 (5): 425-429.

  11. Chiu CT, Chiang WF, Chuang CY, Chan SW. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis. J Oral Maxillofac Surg. 2010; 68 (5): 1055-1063.

  12. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J et al. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg. 2010; 68 (11): 2837-2845.

  13. De Ponte FS. Osteonecrosis of the jaw: a multidisciplinary approach. Italia: Springer-Verlag, 2012.

  14. Allen MR, Burr DB. The pathogenesis of bisphosphonate- related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009; 67 (5 Suppl): 61-70.

  15. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014; 72 (10): 1938-1956.

  16. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008; 66 (4): 625-631.

  17. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29 (8): 1548-1558.

  18. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonaterelated osteonecrosis of the jaw. J Clin Oncol. 2009; 27 (32): 5356-5362.

  19. Coleman RE. Uses and abuses of bisphosphonates. Ann Oncol. 2000; 11 (Suppl 3): 179-184.

  20. Curi MM, Cossolin GS, Koga DH, Zardetto C, Chistianini S, Feher O et al. Bisphosphonate-related osteonecrosis of the jaws. An initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg. 2011; 69 (9): 2465-2472.

  21. Rogers SN, Palmer NO, Lowe D, Randall C. United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. Br J Oral Maxillofac Surg. 2015; 53 (2): 176-182.

  22. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001; 91 (7): 1191-1200.

  23. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62 (5): 527-534.

  24. Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012; 18 (6): 621-623.

  25. Bagan JV, Cibrian RM, Lopez J, Leopolo-Rodado M, Carbonell E, Bagán L et al. Sclerosis in bisphosphonate-related osteonecrosis of the jawsand its correlation with the clinical stages: study of 43 cases. Br J Oral Maxillofac Surg. 2015; 53 (3): 257-262.

  26. Marx RE. Oral and intravenous biphosphonate- induced osteonecrosis of the jaws. Canada. 2da ed. Quintessence Publishing Co., Inc. 2012.

  27. Uyanne J, Calhoun CC, Le AD. Antiresorptive drug–related osteonecrosis of the jaw. Dent Clin N Am. 2014; 58 (2): 369-384.

  28. Yépez GJ, Martínez NP, Gottberg EN. Osteonecrosis de los maxilares inducida por bifosfonatos. Rev Odontol Andes. 2009; 4: 43-54.

  29. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2009; 67 (5 Suppl): 44-52.

  30. Markose G, Fiona R. Mackenzie. Bisphosphonate osteonecrosis: a protocol for surgical management. Br J Oral Maxillofac Surg. 2009; 47 (4): 294-297.

  31. Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012; 21 (8): 810-817.

  32. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al Grbic J. The incidence of osteonecrosis of the jaw in patients receiving 5 mgs of zolendronic acid. Data from the health outcomes and reduced incidence with zolendrónico acid once yearly clinical trials program. J Am Dent Assoc. 2010; 141 (11): 1365-1370.

  33. Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014; 50 (11): 1049-1057.

  34. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012; 41 (11): 1397-1403.

  35. Atanes-Bonome P, Atanes-Bonome A, Ríos-Lagec P, Atanes-Sandovald AD. Osteonecrosis de los maxilares relacionada con el tratamiento con bifosfonatos. Semergen. 2014; 40 (3): 143-148.

  36. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23 (34): 8580-8587.

  37. Pigrau-Serrallach C, Cabral-Galeano E, Almirante-Gragera B, Sordé-Masip R, Rodriguez-Pardo D, Fernandez-Hidalgo N et al. Long-term follow-up of jaw osteomyelitis associated with bisphosphonate use in a tertiary-care center. Enferm Infecc Microbiol Clin. 2014; 32 (1): 18-22.

  38. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011; 8 (2): 90-96.

  39. Ikeda T, Kuraguchi J, Kogashiwa Y, Koyoi H, Satomi T, Kohno N. Successful treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients with sitafloxacin: new strategies for the treatment of BRONJ. Bone. 2015; 73: 217-222.




2020     |     www.medigraphic.com